Gilead Truvada switch study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A study in treatment-experienced HIV patients suggests patients switching from GlaxoSmithKline's Combivir (lamivudine/zidovudine) to Gilead's Truvada (emtricitabine/tenofovir) achieve significantly more viral suppression, Gilead reports Nov. 17. In the Phase IV COMET (Combination of Efavirenz and Truvada) study, presented at the European AIDS Conference Nov. 17 in Dublin, 76% of switched patients had viral load below 50 copies/mL compared to 59% at baseline (p<0.001); efavirenz (Bristol-Myers Squibb's Sustiva) was the background therapy in the study. Gilead has been highlighting Truvada's building sales momentum. Combivir continued to be the market leading nucleoside reverse transcriptase inhibitor in the third quarter, but Truvada sales were up 32%, putting it at the number three slot for the NRTI class (Pharmaceutical Approvals Monthly November 2005, p. 5)...
You may also be interested in...
Gilead’s Truvada Trumps Combivir In Rx Market Share For Therapy Class
Gilead Sciences' combination antiretroviral therapy Truvada (emtricitabine/tenofovir) achieved a market-leading 18.7% of total prescriptions in the nucleoside reverse transcriptase inhibitor class during the third quarter, according to Gilead
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.